Article
Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
Clinical drug investigation - 1 Jul 2017
Lin Chih-Wei, Menon Rajeev, Liu Wei, Podsadecki Thomas, Shulman Nancy, DaSilva-Tillmann Barbara, Awni Walid, Dutta Sandeep
Abstract excerpt
BACKGROUND AND OBJECTIVES: All-oral direct-acting antiviral regimens that include combinations of ombitasvir, paritaprevir, ritonavir, and dasabuvir with or without ribavirin were evaluated in hepatitis C virus-infected patients in phase II/III clinical studies. The objective of these analyses was to quantify the relationship between exposures of the components of the regimen and laboratory values and to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.